The risk factors for Graves’ ophthalmopathy
Authors:
- 17 November 2021
- journal article
- review article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 260 (4) , 1043-1054
Abstract
Purpose This review aimed to provide an overview of current research into the risk factors for Graves’ ophthalmopathy (GO). Methods To find information about the risk factors for GO, the research database PubMed was searched and relevant articles were obtained to extract information about risk factors. Results Smoking has been widely accepted as an important risk factor and cigarette smoking cessation has been shown to improve the outcome and decrease the onset of GO. Radioactive iodine on the thyroid may induce hyperthyroidism and increase the occurrence of GO. Selenium deficiency is a risk factor for GO and the supplementation of selenium has been an adjuvant therapy. Decreasing stressful life events (SLE) may help improve GO. Imbalance in intestinal flora is essential to GO, with Yersinia enterocolitica and Escherichia coli both increased in the digestive tract of the individual with GO. In addition, controlling serum cholesterol may help improve GO since adipogenesis is an important pathological change in its pathogenesis. Considering the correlation between Graves’ disease and GO, maintaining normal thyroid function hormone level is the first-line therapeutic strategy to prevent progression of GO. An increase in antibodies such as TSHR and IGF-1R is the main predictor of GO. Besides, gender and gene polymorphism are also risk factors towards GO. Conclusions Risk factors for GO arise from five sources: physical and chemical environment, social-psychological environment, biological environment, the human organism, and genetic codes. Risk factors within these categories may interact with each other and their mechanisms in promoting the development of GO are complex. Research into risk factors for GO may promote emerging fields related to GO such as control of autoantibodies and intestinal microbiota.Keywords
Funding Information
- National Natural Science Foundation of China (82071006)
- Natural Science Foundation of Hunan Province (2020JJ4129)
- Independent Exploration and Innovation Project of Graduate Students in Central South University (2021zzts1086)
This publication has 100 references indexed in Scilit:
- Thymic stromal lymphopoietin gene promoter polymorphisms and expression levels in Graves’ disease and Graves’ ophthalmopathyBMC Medical Genetics, 2012
- A Stimulatory Thyrotropin Receptor Antibody Enhances Hyaluronic Acid Synthesis in Graves' Orbital Fibroblasts: Inhibition by an IGF-I Receptor Blocking AntibodyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Effect of Smoking on Orbital Fat and Muscle Volume in Graves' OrbitopathyThyroid®, 2011
- Association between interleukin 21 and Graves’ diseaseGenetics and Molecular Research, 2011
- Identification of a Correlation between Helicobacter pylori Infection and Graves’ DiseaseHelicobacter, 2010
- Risk Factors for Development or Deterioration of Graves' OphthalmopathyThyroid®, 2010
- A Stimulatory Thyrotropin Receptor Antibody (M22) and Thyrotropin Increase Interleukin-6 Expression and Secretion in Graves' Orbital Preadipocyte FibroblastsThyroid®, 2010
- Prevalence, Risk Factors, and Clinical Features of Thyroid-Associated Ophthalmopathy in Multiethnic Malaysian Patients with Graves' DiseaseThyroid®, 2008
- Association of Graves’ disease and Graves’ ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 geneJournal of Zhejiang University-SCIENCE B, 2006
- Expression of a human thyrotrophin receptor fragment in Escherichia coli and its interaction with the hormone and autoantibodies from patients with Graves' diseaseJournal of Molecular Endocrinology, 1992